WO2006081779A3 - Preparation pharmaceutique contenant de l'olanzapine en tant que principe actif et son procede de preparation - Google Patents

Preparation pharmaceutique contenant de l'olanzapine en tant que principe actif et son procede de preparation Download PDF

Info

Publication number
WO2006081779A3
WO2006081779A3 PCT/CZ2006/000002 CZ2006000002W WO2006081779A3 WO 2006081779 A3 WO2006081779 A3 WO 2006081779A3 CZ 2006000002 W CZ2006000002 W CZ 2006000002W WO 2006081779 A3 WO2006081779 A3 WO 2006081779A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
pharmaceutical composition
active agent
composition containing
olanzapine
Prior art date
Application number
PCT/CZ2006/000002
Other languages
English (en)
Other versions
WO2006081779A2 (fr
Inventor
Beata Vladovicova
Mikulas Lehocky
Viera Kormanova
Viera Hubinova
Original Assignee
Zentiva As
Beata Vladovicova
Mikulas Lehocky
Viera Kormanova
Viera Hubinova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva As, Beata Vladovicova, Mikulas Lehocky, Viera Kormanova, Viera Hubinova filed Critical Zentiva As
Publication of WO2006081779A2 publication Critical patent/WO2006081779A2/fr
Publication of WO2006081779A3 publication Critical patent/WO2006081779A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une préparation pharmaceutique contenant, en tant que principe actif, de l'olanzapine ainsi qu'un excipient et des substances auxiliaires, sous forme de comprimé obtenu par fabrication directe de comprimé, le noyau du comprimé contenant de l'olanzapine à raison de 0,5 à 20 % en poids et un excipient acceptable au plan pharmaceutique, à raison de 35 à 99 % en poids, de préférence jusqu'à 95 % en poids, la taille des particules étant comprise entre 10 et 1 000, de préférence entre 50 et 400. Le noyau est éventuellement enrobé, auquel cas l'enrobage contient 1 à 10 % en poids de polyéthylèneglycol après séchage. L'excipient acceptable au plan pharmaceutique est choisi dans la série constituée de cellulose microcristalline, du lactose, des polyalcools du type mannitol ou sorbitol, de l'hydrogènephosphate de calcium, et d'une combinaison de la cellulose microcristalline avec un mono- ou un oligosaccharide ou un polyalcool. Un procédé de préparation de comprimés est également décrit.
PCT/CZ2006/000002 2005-02-02 2006-01-19 Preparation pharmaceutique contenant de l'olanzapine en tant que principe actif et son procede de preparation WO2006081779A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20050063A CZ297214B6 (cs) 2005-02-02 2005-02-02 Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
CZPV2005-63 2005-02-02

Publications (2)

Publication Number Publication Date
WO2006081779A2 WO2006081779A2 (fr) 2006-08-10
WO2006081779A3 true WO2006081779A3 (fr) 2007-05-03

Family

ID=36777587

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CZ2006/000002 WO2006081779A2 (fr) 2005-02-02 2006-01-19 Preparation pharmaceutique contenant de l'olanzapine en tant que principe actif et son procede de preparation

Country Status (2)

Country Link
CZ (1) CZ297214B6 (fr)
WO (1) WO2006081779A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR063043A1 (es) * 2006-09-29 2008-12-23 Synthon Bv Composicion farmaceutica de olanzapina
WO2012014012A1 (fr) * 2010-07-27 2012-02-02 Laboratorios Andrómaco S.A. Procédé pour préparer des comprimés à dissolution rapide orale qui comprennent la forme i d'olanzapine, comprimés obtenus et leur utilisation pour le traitement de la schizophrénie
CN103919782B (zh) * 2013-01-15 2016-12-28 天津药物研究院有限公司 一种含有奥氮平的药物组合物及其制备方法
CN103142525B (zh) * 2013-03-21 2015-08-05 江苏豪森药业股份有限公司 奥氮平胃溶型片剂及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0830858A1 (fr) * 1996-09-24 1998-03-25 Eli Lilly And Company Formulation contenant des particules d'olanzapine revêtues
EP1095941A1 (fr) * 1995-03-24 2001-05-02 Eli Lilly & Company Procédé et formes cristallines de 2-methyl-thiénobenzodiazépine
WO2003086361A1 (fr) * 2002-04-18 2003-10-23 Dr. Reddy's Laboratories Ltd. Compositions orales solides a dispersion rapide
WO2004035027A1 (fr) * 2002-10-18 2004-04-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Formulation pharmaceutique d'olanzapine
WO2004091585A1 (fr) * 2003-04-16 2004-10-28 Synthon B.V. Tablettes a desintegration orale

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1095941A1 (fr) * 1995-03-24 2001-05-02 Eli Lilly & Company Procédé et formes cristallines de 2-methyl-thiénobenzodiazépine
EP0830858A1 (fr) * 1996-09-24 1998-03-25 Eli Lilly And Company Formulation contenant des particules d'olanzapine revêtues
WO2003086361A1 (fr) * 2002-04-18 2003-10-23 Dr. Reddy's Laboratories Ltd. Compositions orales solides a dispersion rapide
WO2004035027A1 (fr) * 2002-10-18 2004-04-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Formulation pharmaceutique d'olanzapine
WO2004091585A1 (fr) * 2003-04-16 2004-10-28 Synthon B.V. Tablettes a desintegration orale

Also Published As

Publication number Publication date
WO2006081779A2 (fr) 2006-08-10
CZ200563A3 (cs) 2006-10-11
CZ297214B6 (cs) 2006-10-11

Similar Documents

Publication Publication Date Title
WO2004056363A3 (fr) Materiau particulaire contenant de la nicotine chimiquement et physiquement stable
WO2006127637A3 (fr) Melange compressible, compositions pharmaceutiques comprimees et procede permettant de les preparer
WO2011084593A3 (fr) Formulations empêchant un usage abusif
WO2006128057A3 (fr) Formes posologiques orales contenant du progesterone et procedes de fabrication et d'utilisation desdites formes posologiques
NZ594022A (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
HK1070821A1 (en) Extended release venlafaxine tablet formulation
YU28104A (sh) Oralni oblici davanja propiverina ili njegovih farmaceutski prihvatljivih soli sa produženim oslobađanjem aktivne materije
WO2008057267A3 (fr) Cellulose microcristalline et alcool de sucre co-traités servant d'excipient pour des formulations de comprimés
WO2009034431A3 (fr) Formes posologiques à libération contrôlée de la varenicline
JP2008515980A5 (fr)
WO2006096194A8 (fr) Formulations a liberation immediate de formes de dosage oral de memantine
WO2006053089A3 (fr) Methodes et formulations permettant de preparer des compositions pharmaceutiques contenant du bupropion
MX2008001645A (es) Composiciones de fexofendina en suspension farmaceutica oral.
WO2007077581A3 (fr) Compositions pharmaceutiques
WO2009090670A3 (fr) Composition à libération prolongée stabilisée à base de chlorhydrate de bupropion et procédé de préparation de cette composition
KR960010007A (ko) 게피론 용량형
WO2006081779A3 (fr) Preparation pharmaceutique contenant de l'olanzapine en tant que principe actif et son procede de preparation
ATE329581T1 (de) Pharmazeutische formulierung, die n-((1-n-butyl-4-piperidinyl)menthyl)-3,4-dihydr -2h-(1, 3)oxazino(3,2-a)indol-10-carboxamid oder ein entsprechendes salz hiervon enthält, sowie deren herstellungsprozess, welcher trockengranulierung beinhaltet
WO2008062475A3 (fr) Compositions pharmaceutiques d'ursodiol
EP1177788A3 (fr) Composition pharmaceutique à base de fluoxétine sous forme de comprimés enrobés dispersibles et son procédé de fabrication
WO2008075320A3 (fr) Compositions pharmaceutiques antilipidémiques et leur procédé de préparation
WO2007052307A3 (fr) Formes posologiques solides orales stables de valsartan
WO2011056785A3 (fr) Compositions de cellulose microcristalline et de phosphate de calcium utiles en tant qu'excipients pharmaceutiques
WO2008079343A3 (fr) Comprimés à désintégration par voie orale contenant une dose élevée de principes actifs: composition utilisée et méthodes de fabrication
IL182549A (en) Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06701067

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06701067

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6701067

Country of ref document: EP